Dimensional Fund Advisors LP Acquires 30,891 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH)

Dimensional Fund Advisors LP lifted its holdings in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 2.3% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,347,082 shares of the medical equipment provider's stock after buying an additional 30,891 shares during the quarter. Dimensional Fund Advisors LP owned about 1.94% of Lantheus worth $120,510,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of LNTH. Raymond James Financial Inc. purchased a new stake in shares of Lantheus during the fourth quarter worth $36,183,000. Swedbank AB lifted its holdings in Lantheus by 53.3% during the 4th quarter. Swedbank AB now owns 1,107,243 shares of the medical equipment provider's stock worth $99,054,000 after purchasing an additional 385,000 shares in the last quarter. Keybank National Association OH bought a new position in Lantheus in the 4th quarter worth about $27,526,000. Norges Bank purchased a new position in Lantheus during the 4th quarter valued at about $26,189,000. Finally, Wellington Management Group LLP bought a new stake in shares of Lantheus during the fourth quarter valued at about $20,022,000. 99.06% of the stock is owned by institutional investors.

Insider Buying and Selling

In other news, CFO Robert J. Jr. Marshall sold 10,000 shares of the company's stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $100.52, for a total transaction of $1,005,200.00. Following the completion of the transaction, the chief financial officer now directly owns 113,860 shares of the company's stock, valued at approximately $11,445,207.20. This represents a 8.07 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Mary Anne Heino sold 53,107 shares of the stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $94.35, for a total transaction of $5,010,645.45. Following the sale, the director now owns 440,399 shares of the company's stock, valued at approximately $41,551,645.65. This represents a 10.76 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 63,109 shares of company stock worth $6,016,046 in the last ninety days. 2.00% of the stock is owned by insiders.

Analyst Ratings Changes

LNTH has been the topic of a number of recent analyst reports. B. Riley lowered their price objective on Lantheus from $127.00 to $122.00 and set a "buy" rating on the stock in a research report on Friday, March 21st. Truist Financial lifted their price target on Lantheus from $120.00 to $127.00 and gave the company a "buy" rating in a research report on Thursday, February 27th. Finally, JMP Securities restated a "market outperform" rating and issued a $112.00 price objective on shares of Lantheus in a research report on Tuesday, January 14th. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company's stock. Based on data from MarketBeat, Lantheus currently has a consensus rating of "Moderate Buy" and a consensus price target of $129.43.

Lantheus Trading Down 1.8 %

Shares of Lantheus stock opened at $101.77 on Friday. The business's 50-day moving average price is $97.37 and its 200-day moving average price is $95.23. The firm has a market capitalization of $6.97 billion, a PE ratio of 16.93 and a beta of 0.20. Lantheus Holdings, Inc. has a 12 month low of $65.76 and a 12 month high of $126.89.

Lantheus (NASDAQ:LNTH - Get Free Report) last posted its quarterly earnings results on Thursday, February 27th. The medical equipment provider reported $1.34 EPS for the quarter, missing the consensus estimate of $1.57 by ($0.23). Lantheus had a return on equity of 44.29% and a net margin of 28.57%. The business had revenue of $391.11 million for the quarter, compared to analysts' expectations of $376.61 million. As a group, analysts predict that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current fiscal year.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.

Want to see what other hedge funds are holding LNTH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.